Differential effector engagement by oncogenic KRAS

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890 · see citing works

Silhouettes: A graphical aid to the interpretation and validation of cluster analysis

Rousseeuw, P. J. (1987) · Journal of Computational and Applied Mathematics · doi:10.1016/0377-0427(87)90125-7 · Cited by 21,392 · see citing works

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,869 · see citing works

Systematic identification of genomic markers of drug sensitivity in cancer cells

Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · see citing works

mTOR regulation of autophagy

Jung, C. H., Ro, S.-H., Cao, J., Otto, N. M., & Kim, D.-H. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.017 · Cited by 2,090 · see citing works

A Landscape of Pharmacogenomic Interactions in Cancer

Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090 · see citing works

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943 · see citing works

mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex

Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K., & Puigserver, P. (2007) · Nature · doi:10.1038/nature06322 · Cited by 1,488 · see citing works

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330 · see citing works

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

Guo, J. Y., Chen, H.-Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-Uzunbas, G., Kamphorst, J. J., Chen, G., Lemons, J. M. S., Karantza, V., et al. (2011) · Genes & Development · doi:10.1101/gad.2016311 · Cited by 1,323 · see citing works

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature · doi:10.1038/nature13611 · Cited by 1,259 · see citing works

Nuclear Localization and Regulation of erk- and rsk-Encoded Protein Kinases

Chen, R., Sarnecki, C., & Blenis, J. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.3.915 · Cited by 1,081 · see citing works

Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936 · see citing works

mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation

Morita, M., Gravel, S.-P., Chénard, V., Sikström, K., Zheng, L., Alain, T., Gandin, V., Avizonis, D., Arguello, M., Zakaria, C., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.10.001 · Cited by 842 · see citing works

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841 · see citing works

Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state

Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759 · see citing works

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691 · see citing works

The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity

Aigner, K., Dampier, B., Descovich, L., Mikula, M., Sultan, A., Schreiber, M., Mikulits, W., Brabletz, T., Strand, D., Obrist, P., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210508 · Cited by 618 · see citing works

Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma

Meylan, E., Dooley, A. L., Feldser, D. M., Shen, L., Turk, E., Ouyang, C., & Jacks, T. (2009) · Nature · doi:10.1038/nature08462 · Cited by 514 · see citing works

Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation

Lock, R., Roy, S., Kenific, C. M., Su, J. S., Salas, E., Ronen, S. M., & Debnath, J. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-06-0500 · Cited by 467 · see citing works

A combinatorial strategy for treating KRAS-mutant lung cancer

Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature · doi:10.1038/nature18600 · Cited by 403 · see citing works

Functional identification of optimized RNAi triggers using a massively parallel Sensor assay

Fellmann, C., Zuber, J., McJunkin, K., Chang, K., Malone, C., Dickins, R., Xu, Q.-K., Hengartner, M., Elledge, S., Hannon, G., et al. (2011) · Molecules and Cells · doi:10.1016/j.molcel.2011.02.008 · Cited by 233 · see citing works

Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling

Young, A., Lou, D., & McCormick, F. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0231 · Cited by 211 · see citing works

eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy

Ramírez‐Valle, F., Braunstein, S. E., Zavadil, J., Formenti, S. C., & Schneider, R. J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200710215 · Cited by 191 · see citing works

Prediction of potent shRNAs with a sequential classification algorithm

Pelossof, R. A., Fairchild, L., Huang, C., Widmer, C., Sreedharan, V. T., Sinha, N., Lai, D.-Y., Guan, Y., Premsrirut, P. K., Tschaharganeh, D. F., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3807 · Cited by 177 · see citing works

Requirement for Rac1 in a K-ras–Induced Lung Cancer in the Mouse

Kissil, J. L., Walmsley, M. J., Hanlon, L., Haigis, K. M., Kim, C. F. B., Sweet-Cordero, A., Eckman, M. S., Tuveson, D. A., Capobianco, A. J., Tybulewicz, V. L. J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2300 · Cited by 167 · see citing works

RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 162 · see citing works

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in <i>KRAS</i> -Mutant Lung Cancer

Kitai, H., Ebi, H., Tomida, S., Floros, K. V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., Faber, A. C., & Yano, S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1377 · Cited by 162 · see citing works

Development of siRNA Payloads to Target <i>KRAS</i> -Mutant Cancer

Yuan, T. L., Fellmann, C., Lee, C.-S., Ritchie, C. D., Thapar, V., Lee, L. C., Hsu, D. J., Grace, D., Carver, J. O., Zuber, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0900 · Cited by 113 · see citing works

Ras-dependent carbon metabolism and transformation in mouse fibroblasts

Chiaradonna, F., Sacco, E., Manzoni, R., Giorgio, M., Vanoni, M., & Alberghina, L. (2006) · Oncogene · doi:10.1038/sj.onc.1209528 · Cited by 109 · see citing works

Role of PPAR in Hepatic Carbohydrate Metabolism

Peeters, A., & Baes, M. I. (2010) · PPAR Research · doi:10.1155/2010/572405 · Cited by 102 · see citing works

Peroxisome Proliferator-Activated Receptor-α Control of Lipid and Glucose Metabolism in Human White Adipocytes

Ribet, C., Montastier, É., Valle, C., Bézaire, V., Mazzucotelli, A., Mairal, A., Viguerie, N., & Langin, D. (2009) · Endocrinology · doi:10.1210/en.2009-0726 · Cited by 96 · see citing works

AMPK Inhibits the Stimulatory Effects of TGF-β on Smad2/3 Activity, Cell Migration, and Epithelial-to-Mesenchymal Transition

Lin, H., Li, N., He, H., Ying, Y., Sunkara, S., Luo, L., Lv, N., Huang, D., & Luo, Z. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.099549 · Cited by 95 · see citing works

Enhanced MET Translation and Signaling Sustains K-Ras–Driven Proliferation under Anchorage-Independent Growth Conditions

Fujita-Sato, S., Galeas, J., Truitt, M., Pitt, C., Urisman, A., Bandyopadhyay, S., Ruggero, D., & McCormick, F. P. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1623 · Cited by 54 · see citing works

Dock4 forms a complex with SH3YL1 and regulates cancer cell migration

Kobayashi, M., Harada, K., Negishi, M., & Katoh, H. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.01.027 · Cited by 46 · see citing works

The energy sensor AMPK regulates Hedgehog signaling in human cells through a unique Gli1 metabolic checkpoint

Magno, L. D., Basile, A., Coni, S., Manni, S., Sdruscia, G., D'Amico, D. F., Antonucci, L., Infante, P., Smaele, E. D., Cucchi, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7070 · Cited by 45 · see citing works

The Discovery of Human of GLUD2 Glutamate Dehydrogenase and Its Implications for Cell Function in Health and Disease

Shashidharan, P., & Plaitakis, A. (2014) · Neurochemical Research · doi:10.1007/s11064-013-1227-5 · Cited by 43 · see citing works

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019 · see citing works

EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.

Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504 · see citing works

Therapeutic strategies to target RAS-mutant cancers

Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420 · see citing works

A model for RAS mutation patterns in cancers: finding the sweet spot

Li, S., Balmain, A., & Counter, C. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0076-6 · Cited by 384 · see citing works

KRAS mutation in pancreatic cancer

Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360 · see citing works

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259 · see citing works

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

Koga, T., Suda, K., Fujino, T., Ohara, S., Hamada, A., Nishino, M., Chiba, M., Shimoji, M., Takemoto, T., Arita, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.015 · Cited by 265 · see citing works

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer

Adachi, Y., Ito, K., Hayashi, Y., Kimura, R., Tan, T. Z., Yamaguchi, R., & Ebi, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2077 · Cited by 249 · see citing works

Precision oncology in metastatic colorectal cancer — from biology to medicine

Nicolantonio, F. D., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J. M., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 238 · see citing works

ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications

Yi, M., Nissley, D. V., McCormick, F. P., & Stephens, R. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-66986-8 · Cited by 237 · see citing works

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer

Molina-Arcas, M., Moore, C., Rana, S., van Maldegem, F., Mugarza, E., Romero-Clavijo, P., Herbert, E., Horswell, S., Li, L.-S., Janes, M. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7999 · Cited by 203 · see citing works

Oncogenic KRAS induces NIX-mediated mitophagy to promote pancreatic cancer

Humpton, T. J., Alagesan, B., DeNicola, G. M., Lu, D., Yordanov, G. N., Leonhardt, C. S., Yao, M. A., Alagesan, P., Zaatari, M. N., Park, Y., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1409 · Cited by 198 · see citing works

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

Adderley, H., Blackhall, F. H., & Lindsay, C. R. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.049 · Cited by 196 · see citing works

KRAS drives immune evasion in a genetic model of pancreatic cancer

Ischenko, I., D’Amico, S., Rao, M., Li, J., Hayman, M. J., Powers, S., Petrenko, O., & Reich, N. C. (2021) · Nature Communications · doi:10.1038/s41467-021-21736-w · Cited by 184 · see citing works

Artificial intelligence and machine learning disciplines with the potential to improve the nanotoxicology and nanomedicine fields: a comprehensive review

Singh, A. V., Varma, M., Laux, P., Choudhary, S., Datusalia, A. K., Gupta, N., Luch, A., Gandhi, A., Kulkarni, P., & Nath, B. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03471-x · Cited by 171 · see citing works

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)

Salgia, R., Pharaon, R. R., Mambetsariev, I., Nam, A., & Sattler, M. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100186 · Cited by 163 · see citing works

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00953 · Cited by 129 · see citing works

RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance

Lionarons, D. A., Hancock, D. C., Rana, S., East, P., Moore, C., Murillo, M. M., Carvalho, J., Spencer‐Dene, B., Herbert, E., Stamp, G., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.015 · Cited by 124 · see citing works

MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival

Lee, C.-S., Lee, L. C., Yuan, T. L., Chakka, S., Fellmann, C., Lowe, S. W., Caplen, N. J., McCormick, F., & Luo, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817494116 · Cited by 126 · see citing works

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers

Ozkan‐Dagliyan, I., Diehl, J. N., George, S. D., Schaefer, A., Papke, B., Klotz‐Noack, K., Waters, A. M., Goodwin, C. M., Gautam, P., Pierobon, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107764 · Cited by 102 · see citing works

RAS variant signalling

Mo, S. P., Coulson, J. M., & Prior, I. A. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180173 · Cited by 85 · see citing works

The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives

Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., et al. (2025) · Cancers · doi:10.3390/cancers17030428 · Cited by 82 · see citing works

ADAM17: An Emerging Therapeutic Target for Lung Cancer

Saad, M. I., Rose‐John, S., & Jenkins, B. J. (2019) · Cancers · doi:10.3390/cancers11091218 · Cited by 80 · see citing works

The Function of RAS Mutation in Cancer and Advances in its Drug Research

Chen, S., Li, F., Xu, D., Hou, K., Fang, W., & Li, Y. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190506122228 · Cited by 74 · see citing works

A structural model of a Ras–Raf signalosome

Mysore, V. P., Zhou, Z.-W., Ambrogio, C., Li, L., Kapp, J. N., Lu, C., Wang, Q., Tucker, M. R., Okoro, J. J., Nagy‐Davidescu, G., et al. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00667-6 · Cited by 69 · see citing works

The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?

Oya, Y., Imaizumi, K., & Mitsudomi, T. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107886 · Cited by 72 · see citing works

Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer

Knudsen, E. S., Kumarasamy, V. M., Ruiz, A., Sivinski, J., Chung, S., Grant, A. D., Vail, P. J., Chauhan, S. S., Jie, T., Riall, T. S., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0650-0 · Cited by 64 · see citing works

Progress in targeting RAS with small molecule drugs

McCormick, F. P. (2019) · Biochemical Journal · doi:10.1042/bcj20170441 · Cited by 63 · see citing works

Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives

Zhang, L., Zhang, J., Wang, J., Ren, C., Tang, P., Ouyang, L., & Wang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114176 · Cited by 61 · see citing works

A landscape of response to drug combinations in non-small cell lung cancer

Nair, N. U., Greninger, P., Zhang, X., Friedman, A. A., Amzallag, A., Cortez, E., Sahu, A. D., Lee, J. S., Dastur, A., Egan, R. K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39528-9 · Cited by 58 · see citing works

KRAS: A Druggable Target in Colon Cancer Patients

Negri, F., Bottarelli, L., de’Angelis, G. L., & Gnetti, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084120 · Cited by 55 · see citing works

A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies

Liu, Z., Liu, Y., Qian, L., Jiang, S., Gai, X., Ye, S., Chen, Y., Wang, X., Zhai, L., Xu, J. Q., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.021 · Cited by 54 · see citing works

Epigenetic Input Dictates the Threshold of Targeting of the Integrin-Dependent Pathway in Non-small Cell Lung Cancer

Zhang, Y., Cheng, K., Xu, B., Shi, J., Qiang, J., Shi, S., Yi, Y., Li, H., Jin, T., Guo, R., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00652 · Cited by 53 · see citing works

Integrated multi-omics characterization of KRAS mutant colorectal cancer

Chong, W., Zhu, X., Ren, H., Ye, C., Xu, K., Wang, Z., Jia, S., Shang, L., Li, L., & Chen, H. (2022) · Theranostics · doi:10.7150/thno.73089 · Cited by 53 · see citing works

Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function

Kattan, W. E., Chen, W., Ma, X., Lan, T.-H., van der Hoeven, D., van der Hoeven, R., & Hancock, J. F. (2019) · Life Science Alliance · doi:10.26508/lsa.201900431 · Cited by 45 · see citing works

Membrane curvature sensing of the lipid-anchored K-Ras small GTPase

Hong, L., Mu, H., Jean-Francois, F. L., Lakshman, B., Sarkar‐Banerjee, S., Zhuang, Y., Zeng, Y., Gao, W., Zaske, A. M., Nissley, D. V., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900343 · Cited by 47 · see citing works

The role of wild-type RAS in oncogenic RAS transformation

Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42 · see citing works

KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy

Uniyal, P., Kashyap, V. K., Behl, T., Parashar, D., & Rawat, R. (2025) · Cancers · doi:10.3390/cancers17050785 · Cited by 45 · see citing works

Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations

Burge, R. A., & Hobbs, G. A. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.004 · Cited by 44 · see citing works

Ras assemblies and signaling at the membrane

Nussinov, R., Tsai, C., & Jang, H. (2020) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.01.009 · Cited by 41 · see citing works

Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers

Arner, E. N., Du, W., & Brekken, R. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01049 · Cited by 38 · see citing works

An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors

Indarte, M., Puentes, R., Maruggi, M., Ihle, N. T., Grandjean, G. V., Scott, M. J., Ahmed, Z., Meuillet, E. J., Zhang, S., Lemos, R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2372 · Cited by 37 · see citing works

Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism

Abt, E. R., Rosser, E. W., Durst, M. A., Lok, V. M., Poddar, S., Le, T. M., Cho, A. E.-H., Kim, W., Liu, W., Song, J., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.10.012 · Cited by 37 · see citing works

RAS degraders: The new frontier for RAS-driven cancers

Escher, T. E., & Satchell, K. J. F. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.017 · Cited by 35 · see citing works

Promotion of cancer cell stemness by Ras

Chippalkatti, R., & Abankwa, D. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200964 · Cited by 36 · see citing works

KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges

Ceddia, S., Landi, L. M., & Cappuzzo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169391 · Cited by 33 · see citing works

RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics

Kattan, W. E., & Hancock, J. F. (2020) · Biochemical Journal · doi:10.1042/bcj20190839 · Cited by 31 · see citing works

From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers

Saliani, M., Jalal, R., & Ahmadian, M. R. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0530 · Cited by 26 · see citing works

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers

Adachi, Y., Kimura, R., Hirade, K., & Ebi, H. (2021) · Cancers · doi:10.3390/cancers13205081 · Cited by 28 · see citing works

The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways

Cáceres-Gutiérrez, R. E., Alfaro‐Mora, Y., Andonegui, M. A., Díaz‐Chávez, J., & Herrera, L. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.751367 · Cited by 27 · see citing works

RAS nanoclusters are cell surface transducers that convert extracellular stimuli to intracellular signalling

Zhou, Y., & Hancock, J. F. (2023) · FEBS Letters · doi:10.1002/1873-3468.14569 · Cited by 27 · see citing works

A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors

Fernández‐Pisonero, I., Clavaín, L., Robles‐Valero, J., Lorenzo‐Martín, L. F., Caloto, R., Nieto, B., García-Macías, C., Oeste, C. L., Sánchez‐Martín, M., Abad, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110522 · Cited by 26 · see citing works

Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt

Tanaka, N., & Ebi, H. (2024) · Cancer Science · doi:10.1111/cas.16441 · Cited by 26 · see citing works

Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma

Garcia, N., Pozo, V. D., Yohe, M. E., Goodwin, C. M., Shackleford, T. J., Wang, L., Baxi, K., Chen, Y., Rogojina, A. T., Zimmerman, S. M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0194 · Cited by 23 · see citing works

KRAS-related long noncoding RNAs in human cancers

Saliani, M., Mirzaiebadizi, A., Javadmanesh, A., Siavoshi, A., & Ahmadian, M. R. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00381-x · Cited by 22 · see citing works

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments

Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 22 · see citing works

A brief history of RAS and the RAS Initiative

McCormick, F. P. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.003 · Cited by 19 · see citing works

Context-Dependent Roles of Hes1 in the Adult Pancreas and Pancreatic Tumor Formation

Marui, S., Nishikawa, Y., Shiokawa, M., Yokode, M., Matsumoto, S., Muramoto, Y., Ota, S., Nakamura, T., Yoshida, H. K., Okada, H., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.048 · Cited by 19 · see citing works

Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice

Kurosaki, H., Nakatake, M., Sakamoto, T., Kuwano, N., Yamane, M., Ishii, K., Fujiwara, Y., & Nakamura, T. (2021) · Cells · doi:10.3390/cells10050985 · Cited by 18 · see citing works

Targeting KRAS G12C mutation in lung adenocarcinoma

Rohatgi, A., & Govindan, R. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.12.021 · Cited by 17 · see citing works

Differential expression analysis of genes and long non-coding RNAs associated with KRAS mutation in colorectal cancer cells

Saliani, M., Jalal, R., & Javadmanesh, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-11697-5 · Cited by 17 · see citing works

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer

McAndrews, K. M., Paradiso, F., Stalnecker, C. A., Selvanesan, B. C., Thege, F. I., Peng, D. H., Diaz, B. A. M., Sugimoto, H., Patel, S. I., Mahadevan, K. K., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adt5511 · Cited by 16 · see citing works

RAS G-domains allosterically contribute to the recognition of lipid headgroups and acyl chains

Arora, N., Mu, H., Liang, H., Zhao, W., & Zhou, Y. (2024) · The Journal of Cell Biology · doi:10.1083/jcb.202307121 · Cited by 16 · see citing works

Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants

Post, J. B., Roodhart, J. M. L., & Snippert, H. J. G. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.005 · Cited by 16 · see citing works

KRASG12C inhibitor: combing for combination

Chakraborty, A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200473 · Cited by 14 · see citing works

Synthetic Vulnerabilities in the KRAS Pathway

Román, M., Hwang, E. E., & Sweet-Cordero, A. (2022) · Cancers · doi:10.3390/cancers14122837 · Cited by 12 · see citing works

The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells

Chen, M., Chen, M., Fu, Y., & Zhang, J. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154603 · Cited by 11 · see citing works

Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets

Torres‐Ayuso, P., & Brognard, J. (2019) · Cancers · doi:10.3390/cancers11121972 · Cited by 12 · see citing works

KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition

Fey, S. K., Najumudeen, A. K., Watt, D. M., Millett, L. M., Ford, C. A., Gilroy, K. L., Simpson, R. J., McLay, K., Upstill‐Goddard, R., Chang, D. K.-F., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2709 · Cited by 11 · see citing works

STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancer

D’Amico, S., Kirillov, V., Petrenko, O., & Reich, N. C. (2024) · eLife · doi:10.7554/elife.92559.2 · Cited by 10 · see citing works

AzidoTMT Enables Direct Enrichment and Highly Multiplexed Quantitation of Proteome-Wide Functional Residues

Ma, T. P., Izrael-Tomasevic, A., Mroue, R. M., Budayeva, H. G., Malhotra, S., Raisner, R. M., Evangelista, M., Rose, C. M., Kirkpatrick, D. S., & Yu, K. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00703 · Cited by 10 · see citing works

Small Molecule Imaging Agent for Mutant KRAS G12C

Koch, P. D., Quintana, J. M., Ahmed, M. S., Köhler, R. H., & Weissleder, R. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000290 · Cited by 9 · see citing works

MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Xie, M., Zheng, H., Madan-Lala, R., Dai, W., Gimbrone, N. T., Chen, Z., Kinose, F., Blackstone, S. A., Smalley, K. S. M., Cress, W. D., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0698 · Cited by 9 · see citing works

A feedforward loop between STAT1 and YAP1 stimulates lipid biosynthesis, accelerates tumor growth, and promotes chemotherapy resistance in mutant KRAS colorectal cancer

Wang, S., Diao, S., Kim, H., Zou, J. Y., Li, K., & Koromilas, A. E. (2025) · Communications Biology · doi:10.1038/s42003-025-08740-2 · Cited by 8 · see citing works

BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer

Ohnami, S., Maruyama, K., Chen, K., Takahashi, Y., Ohshima, K., Ohshima, K., Shimoda, Y., Sakai, A., Kamada, F., Nakatani, S., et al. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04172-8 · Cited by 8 · see citing works

Recent advances in lung cancer genomics: Application in targeted therapy

Pathak, N., Chitikela, S. D., & Malik, P. S. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2021.08.004 · Cited by 8 · see citing works

KRAS gene status in gastric signet-ring cell carcinoma patients and acts as biomarker of MEK inhibitor

Wu, N., Huang, Y., Liu, F., Xu, X., Liu, B., & Wei, J. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-617 · Cited by 7 · see citing works

Spa-RQ: an Image Analysis Tool to Visualise and Quantify Spatial Phenotypes Applied to Non-Small Cell Lung Cancer

Bao, J., Walliander, M., Kovács, F., Nagaraj, A. S., Hemmes, A., Sarhadi, V. K., Knuutila, S., Lundin, J. E., Horváth, P., & Verschuren, E. W. (2019) · Scientific Reports · doi:10.1038/s41598-019-54038-9 · Cited by 7 · see citing works

Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds

Pallara, C., Cabot, D., Rivas, J., Brun, S., Seco, J., Abuasaker, B., Tarragó, T., Jaumot, M., Prades, R., & Agell, N. (2022) · Scientific Reports · doi:10.1038/s41598-022-19703-6 · Cited by 7 · see citing works

L-Ascorbic acid preferentially kills KRAS mutant pancreatic cancer cells through DNA damage

Jang, H.-L., Kim, S. T., Hong, J. Y., Jang, K., Heo, J.-S., Chon, H. J., Park, Y. S., & Park, J. O. (2025) · Scientific Reports · doi:10.1038/s41598-025-07668-1 · Cited by 6 · see citing works

Oncogenic dependency plays a dominant role in the immune response to cancer

Li, J., D’Amico, S., Kirillov, V., Petrenko, O., & Reich, N. C. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2308635120 · Cited by 6 · see citing works

Ras proteins as therapeutic targets

Chakraborty, A., Linnane, E., & Ross, S. J. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170529 · Cited by 6 · see citing works

Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling

Li, D., Miermont, A. M., Sable, R. V., Quadri, H. S., Griner, L. A. M., Martin, S. E., Odzorig, T., De, S., Ferrer, M., Powers, A. S., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-1036 · Cited by 5 · see citing works

Evolution of structure-guided drug design strategies targeting mutations in codon 12 of KRAS

Dorandish, S., Bhayekar, K., Singh, A., Kushwaha, N. D., Malin, E., Serafimovski, S., Kelm, J. M., Gavande, N. S., & Lakkaniga, N. R. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00169b · Cited by 5 · see citing works

Cell cycle dependence of ERK activation dynamics is regulated by PI3K and PAK1 signaling

Yoshizawa, R., & Sako, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-13686-w · Cited by 6 · see citing works

The integrated stress response in the induction of mutant KRAS lung carcinogenesis: Mechanistic insights and therapeutic implications

Koromilas, A. (2022) · Bioessays · doi:10.1002/bies.202200026 · Cited by 3 · see citing works

Association of the KRAS genotype and clinicopathologic findings of resected non‐small‐cell lung cancer: A pooled analysis of 179 patients

Masago, K., Kuroda, H., Sasaki, E., Fujita, S., Shinohara, S., Sugita, Y., Takahashi, Y., & Matsushita, H. (2022) · Cancer Genetics · doi:10.1016/j.cancergen.2022.09.004 · Cited by 5 · see citing works

Classification of GTP-dependent K-Ras4B active and inactive conformational states

Narayan, B., Kiel, C., & Buchete, N. (2023) · The Journal of Chemical Physics · doi:10.1063/5.0139181 · Cited by 5 · see citing works

Mutant KRAS-Associated Proteome Is Mainly Controlled by Exogenous Factors

Carvalho, P. D., Martins, F., Carvalho, J., Oliveira, M. J., & Velho, S. (2022) · Cells · doi:10.3390/cells11131988 · Cited by 5 · see citing works

A landscape of synergistic drug combinations in non-small-cell lung cancerPreprint

Nair, N. U., Greninger, P., Friedman, A. A., Amzallag, A., Cortez, E., Sahu, A. D., Lee, J. S., Dastur, A., Egan, R. K., Murchie, E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.03.447011 · Cited by 5 · see citing works

Erk1R84H is an oncoprotein that causes hepatocellular carcinoma in mice and imposes a rigorous negative feedback loop

Soudah, N., Baskin, A., Darash‐Yahana, M., Darlyuk‐Saadon, I., Smorodinsky-Atias, K., Shalit, T., Yu, W., Savidor, A., Pikarsky, E., & Engelberg, D. (2025) · Oncogene · doi:10.1038/s41388-025-03437-6 · Cited by 4 · see citing works

Recombinant Strains of Oncolytic Vaccinia Virus for Cancer Immunotherapy

Shakiba, Y., Vorobyev, P. O., Mahmoud, M., Hamad, A., Кочетков, Д. В., Yusubalieva, G. M., Baklaushev, V. P., Chumakov, P. M., & Lipatova, A. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s000629792306010x · Cited by 4 · see citing works

Insulated Switches: Dual-Function Protein RalGEFRGL-1 Promotes Developmental Fidelity

Duong, T., Rasmussen, N. R., & Reiner, D. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207610 · Cited by 4 · see citing works

Intratumor heterogeneity in KRAS signaling shapes treatment resistance

Petrenko, O., Kirillov, V., D’Amico, S., & Reich, N. C. (2024) · iScience · doi:10.1016/j.isci.2024.111662 · Cited by 3 · see citing works

In Situ RAS:RAF Binding Correlates with Response to KRASG12C Inhibitors in KRAS G12C-Mutant Non–Small Cell Lung Cancer

Kato, R., Solanki, H. S., Özakıncı, H., Desai, B., Gundlapalli, H., Yang, Y. C., Aronchik, I., Singh, M., Johnson, J., Marusyk, A., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3714 · Cited by 3 · see citing works

Regional and Gender-Based Distribution of KRAS Mutations in Metastatic Colorectal Cancer Patients in Turkey: An Observational Study

İlhan, N., Dane, F., Göker, E., Uygun, K., Orhan, B., Okutur, K., Ünek, İ. T., Işıkdoğan, A., Bilici, A. E., Zengin, N., et al. (2025) · Medicina · doi:10.3390/medicina61040694 · Cited by 3 · see citing works

KRAS mutations in colorectal cancer: impacts on tumor microenvironment and therapeutic implications

Emami, A., Sharif, P. M., & Rezaei, N. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2500426 · Cited by 3 · see citing works

KRAS: Structure, function, and development of anticancer drugs

Parasrampuria, D. A., Yu, A., & Haddish‐Berhane, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818168-3.00013-9 · Cited by 3 · see citing works

KRAS Addiction Promotes Cancer Cell Adaptation in Harsh Microenvironment Through Macropinocytosis

Seguin, L. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-94004-1_10 · Cited by 3 · see citing works

NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs

Iraqi, M., Bolel, P., Sarkar, R., Bhattacharya, B., Ahmad, M. A., Edri, A., Roisman, L. C., Elkabets, M., Shalata, W., Peled, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214054 · Cited by 3 · see citing works

Mapping Effector–Phenotype Landscapes in KRAS-Driven Cancers

Winter, P. S., & Wood, K. C. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.02.004

Abstract 4690: Next-generation screen for integrative subtyping and target discovery for KRAS-mutant cancer

Yuan, T. L., Bagni, R., Yi, M., Amzallag, A., Afghani, S., Beam, K., Burgan, W. E., Fer, N. D., Garvey, L. A., Smith, B., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-4690

Abstract PR13: Systems and structural biology approaches to elucidate new effectors in KRAS mutant tumors

Broyde, J., Simpson, D. R., Wah, D. A., Giorgi, F. M., Petrey, D. S., Alvarez, M. J., Silkov, A., Lachmann, A., HILL, D. E., Vidal, M., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.compsysbio-pr13

Abstract 1355: Linking AP/MS-derived protein-protein interaction networks and pairwise sgRNA screens defines new KRAS effectors in non-small cell lung cancer

Kelly, M. R. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-1355

Characterization of effector binding preferences between oncogenic mutants KRAS4b G12D and KRAS4b G12C

Rigby, M. (2022) · Maryland Shared Open Access Repository (USMAI Consortium) · doi:10.13016/m2p3dv-bi7k